DexCom Inc. (NASDAQ: DXCM)’s stock price has increased by 2.26 compared to its previous closing price of 110.66. However, the company has seen a fall of -0.57% in its stock price over the last five trading days. Barron’s reported on 10/28/22 that Dexcom Stock Soars on Earnings and Revenue Beat
Is It Worth Investing in DexCom Inc. (NASDAQ: DXCM) Right Now?
DexCom Inc. (NASDAQ: DXCM) has a price-to-earnings ratio that is above its average at 141.27x. and a 36-month beta value of 1.16. Opinions on the stock are mixed, with 14 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The average price predicted for DexCom Inc. (DXCM) by analysts is $132.74, which is $19.58 above the current market price. The public float for DXCM is 384.65M, and at present, short sellers hold a 3.36% of that float. On March 15, 2023, the average trading volume of DXCM was 2.60M shares.
DXCM’s Market Performance
DXCM’s stock has seen a -0.57% decrease for the week, with a -4.01% drop in the past month and a -2.83% fall in the past quarter. The volatility ratio for the week is 3.88%, and the volatility levels for the past 30 days are at 3.43% for DexCom Inc. The simple moving average for the last 20 days is -0.89% for DXCM stock, with a simple moving average of 16.10% for the last 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Wolfe Research repeating the rating for DXCM by listing it as a “Outperform.” The predicted price for DXCM in the upcoming period, according to Wolfe Research is $121 based on the research report published on January 26th of the current year 2023.
Barclays, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $103. The rating they have provided for DXCM stocks is “Equal Weight” according to the report published on October 18th, 2022.
Jefferies gave a rating of “Buy” to DXCM, setting the target price at $125 in the report published on October 12th of the previous year.
DXCM Trading at 1.84% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.03% of loss for the given period.
Volatility was left at 3.43%, however, over the last 30 days, the volatility rate increased by 3.88%, as shares sank -4.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.97% upper at present.
During the last 5 trading sessions, DXCM fell by -0.57%, which changed the moving average for the period of 200-days by +60.90% in comparison to the 20-day moving average, which settled at $113.92. In addition, DexCom Inc. saw -0.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Dolan Matthew Vincent, who sale 6,229 shares at the price of $106.27 back on Mar 13. After this action, Dolan Matthew Vincent now owns 35,872 shares of DexCom Inc., valued at $661,956 using the latest closing price.
Flynn Paul R, the EVP Global Revenue of DexCom Inc., sale 2,782 shares at $106.27 during a trade that took place back on Mar 13, which means that Flynn Paul R is holding 54,893 shares at $295,643 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- +13.44 for the present operating margin
- +64.46 for the gross margin
The net margin for DexCom Inc. stands at +11.73. Equity return is now at value 16.20, with 6.60 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
To sum up, DexCom Inc. (DXCM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
